Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled...
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Adult | Diphosphonates - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Imidazoles - adverse effects | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Diphosphonates - administration & dosage | Zoledronic Acid | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Adult | Diphosphonates - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Imidazoles - adverse effects | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Diphosphonates - administration & dosage | Zoledronic Acid | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. e28 - e37
Summary The management of metastatic solid tumours has historically focused on systemic treatment given with palliative intent. However, radical surgical...
Hematology, Oncology and Palliative Medicine | LONG-TERM | BREAST-CANCER | LUNG | ONCOLOGY | ADRENAL-GLAND METASTASES | COLORECTAL-CANCER | INTENSITY-MODULATED RADIOTHERAPY | PHASE-II | LOCAL-CONTROL | RADIATION-THERAPY SBRT | SPINAL METASTASES | Disease-Free Survival | Lung Neoplasms - secondary | Neoplasm Metastasis - radiotherapy | Neoplasm Metastasis - pathology | Humans | Liver Neoplasms - radiotherapy | Lung Neoplasms - radiotherapy | Dose Fractionation | Radiotherapy, Image-Guided | Liver Neoplasms - secondary | Radiosurgery - methods | Research | Radiotherapy | Nuclear radiation | Oncology, Experimental | Health care reform | Cancer
Hematology, Oncology and Palliative Medicine | LONG-TERM | BREAST-CANCER | LUNG | ONCOLOGY | ADRENAL-GLAND METASTASES | COLORECTAL-CANCER | INTENSITY-MODULATED RADIOTHERAPY | PHASE-II | LOCAL-CONTROL | RADIATION-THERAPY SBRT | SPINAL METASTASES | Disease-Free Survival | Lung Neoplasms - secondary | Neoplasm Metastasis - radiotherapy | Neoplasm Metastasis - pathology | Humans | Liver Neoplasms - radiotherapy | Lung Neoplasms - radiotherapy | Dose Fractionation | Radiotherapy, Image-Guided | Liver Neoplasms - secondary | Radiosurgery - methods | Research | Radiotherapy | Nuclear radiation | Oncology, Experimental | Health care reform | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 464 - 473
Summary Background The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with...
Hematology, Oncology and Palliative Medicine | ANDROGEN-DEPRIVATION THERAPY | EXTERNAL-BEAM RADIOTHERAPY | LOW-RISK | ONCOLOGY | NEOADJUVANT HORMONE-THERAPY | RATE BRACHYTHERAPY | MEN | RADICAL PROSTATECTOMY | TOXICITY | SUPPRESSION | RADIATION-THERAPY | Prostatic Neoplasms - radiotherapy | Humans | Middle Aged | Male | Time Factors | Aged, 80 and over | Prostatic Neoplasms - blood | Dose Fractionation | Neoadjuvant Therapy | Kallikreins - blood | Chemotherapy, Adjuvant | Prostatic Neoplasms - pathology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Disease-Free Survival | Radiotherapy, Conformal - mortality | Intention to Treat Analysis | Androgen Antagonists - therapeutic use | Radiotherapy, Conformal - adverse effects | Aged | Neoplasm Staging | Clinical trials | Radiotherapy
Hematology, Oncology and Palliative Medicine | ANDROGEN-DEPRIVATION THERAPY | EXTERNAL-BEAM RADIOTHERAPY | LOW-RISK | ONCOLOGY | NEOADJUVANT HORMONE-THERAPY | RATE BRACHYTHERAPY | MEN | RADICAL PROSTATECTOMY | TOXICITY | SUPPRESSION | RADIATION-THERAPY | Prostatic Neoplasms - radiotherapy | Humans | Middle Aged | Male | Time Factors | Aged, 80 and over | Prostatic Neoplasms - blood | Dose Fractionation | Neoadjuvant Therapy | Kallikreins - blood | Chemotherapy, Adjuvant | Prostatic Neoplasms - pathology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Disease-Free Survival | Radiotherapy, Conformal - mortality | Intention to Treat Analysis | Androgen Antagonists - therapeutic use | Radiotherapy, Conformal - adverse effects | Aged | Neoplasm Staging | Clinical trials | Radiotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 9, pp. 872 - 876
Summary Background Bisphosphonates might modulate the development of symptomatic bone metastases in men with prostate cancer. The Medical Research Council...
Hematology, Oncology and Palliative Medicine | ANDROGEN SUPPRESSION | ZOLEDRONIC ACID | BISPHOSPHONATES | ONCOLOGY | DOUBLE-BLIND | STAMPEDE | SYSTEMIC THERAPY | MULTIARM | BREAST | Prostatic Neoplasms - pathology | Follow-Up Studies | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Proportional Hazards Models | Bone Neoplasms - secondary | Male | Bone Density Conservation Agents - administration & dosage | Randomized Controlled Trials as Topic | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Neoplasms - prevention & control | Survival Analysis | Clodronic Acid - administration & dosage | Bone Neoplasms - drug therapy | Chemotherapy, Adjuvant | Prostatic Neoplasms - drug therapy | Metastasis | Research | Patient outcomes | Oncology, Experimental | Diphosphonates | Cancer | Fast track
Hematology, Oncology and Palliative Medicine | ANDROGEN SUPPRESSION | ZOLEDRONIC ACID | BISPHOSPHONATES | ONCOLOGY | DOUBLE-BLIND | STAMPEDE | SYSTEMIC THERAPY | MULTIARM | BREAST | Prostatic Neoplasms - pathology | Follow-Up Studies | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Proportional Hazards Models | Bone Neoplasms - secondary | Male | Bone Density Conservation Agents - administration & dosage | Randomized Controlled Trials as Topic | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Neoplasms - prevention & control | Survival Analysis | Clodronic Acid - administration & dosage | Bone Neoplasms - drug therapy | Chemotherapy, Adjuvant | Prostatic Neoplasms - drug therapy | Metastasis | Research | Patient outcomes | Oncology, Experimental | Diphosphonates | Cancer | Fast track
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 65 - 77
Summary Background Several studies have reported associations between radiation toxicity and single nucleotide polymorphisms (SNPs) in candidate genes. Few...
Hematology, Oncology and Palliative Medicine | ACID SUBSTITUTION VARIANTS | THERAPY FOLLOWING LUMPECTOMY | G CHROMOSOMAL RADIOSENSITIVITY | ONCOLOGY | NORMAL TISSUE-REACTIONS | ATM SEQUENCE VARIANTS | BREAST-CANCER PATIENTS | DNA-REPAIR GENES | RANDOMIZED CONTROLLED-TRIAL | SINGLE NUCLEOTIDE POLYMORPHISMS | GENOME-WIDE ASSOCIATION | Genetic Predisposition to Disease | Prostatic Neoplasms - radiotherapy | Prospective Studies | Risk Assessment | Gene Frequency | Humans | Risk Factors | Linear Models | Male | United Kingdom | Radiotherapy, Intensity-Modulated - adverse effects | Breast Neoplasms - radiotherapy | Breast Neoplasms - genetics | Prostatic Neoplasms - genetics | Radiation Injuries - genetics | Time Factors | Radiotherapy, Adjuvant - adverse effects | Dose Fractionation | Female | Radiation Injuries - pathology | Polymorphism, Single Nucleotide | Odds Ratio | Dose-Response Relationship, Radiation | Nuclear radiation | Oncology, Experimental | Analysis | Genes | Genetic research | Genetic aspects | Research | Cancer
Hematology, Oncology and Palliative Medicine | ACID SUBSTITUTION VARIANTS | THERAPY FOLLOWING LUMPECTOMY | G CHROMOSOMAL RADIOSENSITIVITY | ONCOLOGY | NORMAL TISSUE-REACTIONS | ATM SEQUENCE VARIANTS | BREAST-CANCER PATIENTS | DNA-REPAIR GENES | RANDOMIZED CONTROLLED-TRIAL | SINGLE NUCLEOTIDE POLYMORPHISMS | GENOME-WIDE ASSOCIATION | Genetic Predisposition to Disease | Prostatic Neoplasms - radiotherapy | Prospective Studies | Risk Assessment | Gene Frequency | Humans | Risk Factors | Linear Models | Male | United Kingdom | Radiotherapy, Intensity-Modulated - adverse effects | Breast Neoplasms - radiotherapy | Breast Neoplasms - genetics | Prostatic Neoplasms - genetics | Radiation Injuries - genetics | Time Factors | Radiotherapy, Adjuvant - adverse effects | Dose Fractionation | Female | Radiation Injuries - pathology | Polymorphism, Single Nucleotide | Odds Ratio | Dose-Response Relationship, Radiation | Nuclear radiation | Oncology, Experimental | Analysis | Genes | Genetic research | Genetic aspects | Research | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 549 - 558
Summary Background Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE—an international,...
Hematology, Oncology and Palliative Medicine | SURVIVAL | PLACEBO | PREDNISONE | MITOXANTRONE | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | CYCLOOXYGENASE-2 INHIBITORS | RADIUM-223 | OUTCOMES | DOCETAXEL | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Celecoxib | Gonadotropin-Releasing Hormone - analogs & derivatives | Orchiectomy | Prostatic Neoplasms - therapy | Sulfonamides - therapeutic use | Androgen Antagonists - therapeutic use | Aged | Analysis | Oncology, Experimental | Clinical trials | Angiogenesis inhibitors | Metastasis | Nonsteroidal anti-inflammatory drugs | Research | Cancer
Hematology, Oncology and Palliative Medicine | SURVIVAL | PLACEBO | PREDNISONE | MITOXANTRONE | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | CYCLOOXYGENASE-2 INHIBITORS | RADIUM-223 | OUTCOMES | DOCETAXEL | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Celecoxib | Gonadotropin-Releasing Hormone - analogs & derivatives | Orchiectomy | Prostatic Neoplasms - therapy | Sulfonamides - therapeutic use | Androgen Antagonists - therapeutic use | Aged | Analysis | Oncology, Experimental | Clinical trials | Angiogenesis inhibitors | Metastasis | Nonsteroidal anti-inflammatory drugs | Research | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. e139 - e147
Summary New gastrointestinal symptoms are frequent after pelvic radiotherapy and can greatly affect the quality of life of cancer survivors. The effect of...
Hematology, Oncology and Palliative Medicine | GASTROINTESTINAL TOXICITY | MOUSE INTESTINE | IMMUNE-SYSTEM | ONCOLOGY | INTESTINAL MICROBIOTA | PELVIC RADIOTHERAPY | FECAL MICROBIOTA | ULCERATIVE-COLITIS | GUT MICROBIOTA | RECURRENT CLOSTRIDIUM-DIFFICILE | NF-KAPPA-B | Symbiosis | Microbiota | Animals | Intestines - microbiology | Radiation Injuries | Humans | Intestines - radiation effects | Neoplasms - radiotherapy | Radiotherapy - adverse effects | Inflammatory Bowel Diseases - complications | Microbiota (Symbiotic organisms) | Radiotherapy | Gastrointestinal diseases | Radiation
Hematology, Oncology and Palliative Medicine | GASTROINTESTINAL TOXICITY | MOUSE INTESTINE | IMMUNE-SYSTEM | ONCOLOGY | INTESTINAL MICROBIOTA | PELVIC RADIOTHERAPY | FECAL MICROBIOTA | ULCERATIVE-COLITIS | GUT MICROBIOTA | RECURRENT CLOSTRIDIUM-DIFFICILE | NF-KAPPA-B | Symbiosis | Microbiota | Animals | Intestines - microbiology | Radiation Injuries | Humans | Intestines - radiation effects | Neoplasms - radiotherapy | Radiotherapy - adverse effects | Inflammatory Bowel Diseases - complications | Microbiota (Symbiotic organisms) | Radiotherapy | Gastrointestinal diseases | Radiation
Journal Article
The Lancet, ISSN 0140-6736, 12/2018, Volume 392, Issue 10162, pp. 2353 - 2366
Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that...
SURVIVAL | MEDICINE, GENERAL & INTERNAL | MEN | RADICAL PROSTATECTOMY | TIME | BONE | ANDROGEN DEPRIVATION THERAPY | RADIATION-THERAPY | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Lymph Nodes - pathology | Prostatic Neoplasms - surgery | Standard of Care | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Radiotherapy - adverse effects | Orchiectomy | Disease-Free Survival | Neoplasm Metastasis | Survival Analysis | Docetaxel - therapeutic use | Aged | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Metastasis | Radiotherapy | Prostate cancer | Analysis | Drug abuse | Substance abuse treatment | Prostate-specific antigen | Radiation | Bladder | Subgroups | Metastases | Randomization | Motivation | Nonsteroidal anti-inflammatory drugs | Urogenital system | Medical research | Aspirin | Deprivation | Hazards | Inflammation | Radiation therapy | Patients | Survival | Androgens | Hypotheses | Medical prognosis | Men | Prostate | Cancer | Tumors
SURVIVAL | MEDICINE, GENERAL & INTERNAL | MEN | RADICAL PROSTATECTOMY | TIME | BONE | ANDROGEN DEPRIVATION THERAPY | RADIATION-THERAPY | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Lymph Nodes - pathology | Prostatic Neoplasms - surgery | Standard of Care | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Radiotherapy - adverse effects | Orchiectomy | Disease-Free Survival | Neoplasm Metastasis | Survival Analysis | Docetaxel - therapeutic use | Aged | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Metastasis | Radiotherapy | Prostate cancer | Analysis | Drug abuse | Substance abuse treatment | Prostate-specific antigen | Radiation | Bladder | Subgroups | Metastases | Randomization | Motivation | Nonsteroidal anti-inflammatory drugs | Urogenital system | Medical research | Aspirin | Deprivation | Hazards | Inflammation | Radiation therapy | Patients | Survival | Androgens | Hypotheses | Medical prognosis | Men | Prostate | Cancer | Tumors
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1047 - 1060
Summary Background Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We...
Hematology, Oncology and Palliative Medicine | EXTERNAL-BEAM RADIOTHERAPY | METAANALYSIS | ONCOLOGY | CONFORMAL RADIOTHERAPY | FRACTIONATED RADIOTHERAPY | MEN | RISK | ACUTE TOXICITY | RADIATION-THERAPY | ALPHA/BETA RATIO | ESCALATION | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Humans | Middle Aged | Radiotherapy, Intensity-Modulated - methods | Risk Factors | Male | Survival Rate | Treatment Outcome | Dose Hypofractionation | International Agencies | Aged, 80 and over | Aged | Neoplasm Staging | Hospitals | Research institutes | Radiotherapy | Prostate cancer | Analysis | Radiation
Hematology, Oncology and Palliative Medicine | EXTERNAL-BEAM RADIOTHERAPY | METAANALYSIS | ONCOLOGY | CONFORMAL RADIOTHERAPY | FRACTIONATED RADIOTHERAPY | MEN | RISK | ACUTE TOXICITY | RADIATION-THERAPY | ALPHA/BETA RATIO | ESCALATION | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Humans | Middle Aged | Radiotherapy, Intensity-Modulated - methods | Risk Factors | Male | Survival Rate | Treatment Outcome | Dose Hypofractionation | International Agencies | Aged, 80 and over | Aged | Neoplasm Staging | Hospitals | Research institutes | Radiotherapy | Prostate cancer | Analysis | Radiation
Journal Article